Samir Abu-Rumeileh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7483302/publications.pdf

Version: 2024-02-01

220 papers

12,305 citations

23567 58 h-index 99 g-index

226 all docs 226 docs citations

times ranked

226

14232 citing authors

#	Article	IF	CITATIONS
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
2	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	1.9	7
3	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission, 2022, 129, 207-230.	2.8	26
4	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
5	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
6	Diagnostic and Prognostic Blood Biomarkers in Transient Ischemic Attack and Minor Ischemic Stroke: An Up-To-Date Narrative Review. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106292.	1.6	5
7	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
8	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1664.	4.1	11
9	A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke Journal of the Neurological Sciences, 2022, 432, 120090.	0.6	3
10	Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 422-435.	1.9	22
11	Blood \hat{I}^2 -Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.000000000000200002.	1.1	11
12	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
13	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	3.9	30
14	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nature Reviews Neurology, 2022, 18, 158-172.	10.1	205
15	Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldt–Jakob Disease. International Journal of Molecular Sciences, 2022, 23, 2051.	4.1	5
16	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
17	Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. Multiple Sclerosis Journal, 2022, 28, 1553-1561.	3.0	20
18	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	3.6	1

#	Article	IF	Citations
19	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
20	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	4.0	5
21	Serum <scp>Beta‧ynuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp> . Annals of Neurology, 2022, 92, 6-10.	5.3	9
22	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	1.9	12
23	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
24	Acute stroke-like deficits associated with nonketotic hyperglycemic hyperosmolar state: an illustrative case and systematic review of literature. Neurological Sciences, 2022, 43, 4671-4683.	1.9	5
25	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
26	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
27	Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 2022, 19, 1248-1258.	4.4	46
28	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	1.9	21
29	Factors associated with mortality in early stages of parkinsonism. Npj Parkinson's Disease, 2022, 8, .	5.3	4
30	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	3.9	12
31	Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 204-215.	1.9	62
32	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
33	Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology, 2021, 268, 1133-1170.	3.6	286
34	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury. Burns and Trauma, 2021, 9, tkab027.	4.9	4
35	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
36	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14

#	Article	IF	CITATIONS
37	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	1.5	1
38	Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art. Frontiers in Neuroscience, 2021, 15, 648743.	2.8	14
39	Protein Binding Partners of Dysregulated miRNAs in Parkinson's Disease Serum. Cells, 2021, 10, 791.	4.1	11
40	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 946-958.	0.8	16
41	Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barr \tilde{A} syndrome. Brain, 2021, 144, e44-e44.	7.6	6
42	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	2.6	18
43	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging, 2021, 1, 521-534.	11.6	64
44	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 679199.	2.8	66
45	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10
46	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
47	The clinical spectrum of multisystem proteinopathy: Data from a neurodegenerative cohort. Journal of the Neurological Sciences, 2021, 426, 117478.	0.6	3
48	Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 330.	2.7	12
49	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration, 2021, 10, 31.	8.0	18
50	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
51	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	3.1	34
52	Disease-related cortical thinning in presymptomatic granulin mutation carriers. Neurolmage: Clinical, 2021, 29, 102540.	2.7	8
53	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
54	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. Journal of Alzheimer's Disease, 2021, 84, 1153-1161.	2.6	11

#	Article	IF	CITATIONS
55	Varicella Âzoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. Journal of Neurology, 2021, , 1.	3.6	10
56	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. Expert Review of Proteomics, 2021, 18, 977-994.	3.0	5
57	Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1. Sleep, 2020, 43, .	1.1	6
58	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology, 2020, 267, 36-44.	3.6	47
59	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	1.9	16
60	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathologica, 2020, 139, 119-134.	7.7	73
61	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	7.4	252
62	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	6.2	86
63	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
64	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. Clinica Chimica Acta, 2020, 502, 199-200.	1.1	0
65	Disentangling brain functional network remodeling in corticobasal syndrome – A multimodal MRI study. Neurolmage: Clinical, 2020, 25, 102112.	2.7	10
66	Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. World Journal of Biological Psychiatry, 2020, 21, 148-154.	2.6	18
67	Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections. Cells, 2020, 9, 2169.	4.1	3
68	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. Journal of Virological Methods, 2020, 286, 113965.	2.1	10
69	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. Scientific Reports, 2020, 10, 8776.	3.3	4
70	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	1.9	12
71	Millerâ€Fisher syndrome after COVIDâ€19: neurochemical markers as an early sign of nervous system involvement. European Journal of Neurology, 2020, 27, 2378-2380.	3.3	51
72	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	1.9	36

#	Article	IF	CITATIONS
73	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	7.7	8
74	Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. Journal of the Neurological Sciences, 2020, 418, 117106.	0.6	17
75	Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1181-1188.	1.9	34
76	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
77	Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance. Proceedings of the Nutrition Society, 2020, 79, .	1.0	1
78	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. BMC Neurology, 2020, 20, 227.	1.8	6
79	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.7	15
80	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	10.8	46
81	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
82	Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1699-1708.	3.6	39
83	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
84	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
85	CSF SerpinA1 in Creutzfeldt–Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	3.7	16
86	S-ketamine induces acute changes in the proteome of the mouse amygdala. Journal of Proteomics, 2020, 216, 103679.	2.4	6
87	CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. Biomolecules, 2020, 10, 497.	4.0	8
88	Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. Acta Neuropathologica Communications, 2020, 8, 61.	5.2	58
89	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	1.9	55
90	Guillain-Barr \tilde{A} © syndrome following COVID-19: new infection, old complication?. Journal of Neurology, 2020, 267, 1877-1879.	3.6	171

#	Article	IF	Citations
91	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
92	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Translational Psychiatry, 2020, 10, 144.	4.8	20
93	Antemortem CSF A $<$ i $>$ Î $<$ $<$ I $>$ 42/A $<$ i $>$ Î $<$ $<$ I $>$ 40 ratio predicts Alzheimer's disease pathology better than A $<$ i $>$ Î $<$ I $>$ I $>$ 42 in rapidly progressive dementias. Annals of Clinical and Translational Neurology, 2019, 6, 263-273.	3.7	31
94	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 114.	5.2	11
95	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal of Molecular Sciences, 2019, 20, 4674.	4.1	26
96	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. Clinica Chimica Acta, 2019, 498, 148-153.	1.1	7
97	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
98	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
99	Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1068.2-1069.	1.9	44
100	Diagnostic value of surrogate CSF biomarkers for Creutzfeldt–Jakob disease in the era of RT-QulC. Journal of Neurology, 2019, 266, 3136-3143.	3.6	44
101	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	2.6	171
102	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	4.8	28
103	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	3.5	41
104	Advantages and disadvantages of the use of the CSF Amyloid \hat{l}^2 (A \hat{l}^2) 42/40 ratio in the diagnosis of Alzheimer $\hat{a} \in \mathbb{R}$ Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	6.2	325
105	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. Frontiers in Immunology, 2019, 10, 641.	4.8	34
106	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. Journal of Alzheimer's Disease, 2019, 68, 723-733.	2.6	21
107	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 2019, 92, e1479-e1486.	1.1	100
108	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17

#	Article	IF	CITATIONS
109	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
110	A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918.	3.3	91
111	Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	5.2	29
112	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Frontiers in Neurology, 2019, 10, 1179.	2.4	18
113	Transverse Sinus Stenosis in Refractory Chronic Headache Patients: An Observational Study. Frontiers in Neurology, 2019, 10, 1287.	2.4	7
114	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
115	Neurochemical biomarkers in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2019, 32, 747-757.	3.6	24
116	A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. Neurology and Therapy, 2019, 8, 113-127.	3.2	35
117	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
118	Biomarkers for diseases with TDP-43 pathology. Molecular and Cellular Neurosciences, 2019, 97, 43-59.	2.2	38
119	"Microchip Electrophoresis,―with Respect to "Profiling of Aβ Peptides in the Cerebrospinal Fluid of Patients with Alzheimer's Disease― Methods in Molecular Biology, 2019, 1855, 327-340.	0.9	4
120	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	1.9	174
121	Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 12-18.	1.7	7
122	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
123	Story of the ALS-FTD continuum retold: rather two distinct entities. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 586-589.	1.9	26
124	Analysis of CACNA1A CAG repeat lengths in patients with familialÂALS. Neurobiology of Aging, 2019, 74, 235.e5-235.e8.	3.1	6
125	Comprehensive micro <scp>RNA</scp> expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathology and Applied Neurobiology, 2019, 45, 318-323.	3.2	1
126	The cryo-electron microscopy structure of huntingtin. Nature, 2018, 555, 117-120.	27.8	125

#	Article	IF	Citations
127	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
128	Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans. Peptides, 2018, 102, 26-30.	2.4	5
129	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	3.1	6
130	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	1.9	80
131	Identification of rare genetic variants in Italian patients with dementia by targeted gene sequencing. Neurobiology of Aging, 2018, 66, 180.e23-180.e31.	3.1	18
132	The molecular tweezer CLR01 inhibits Ebola and Zika virus infection. Antiviral Research, 2018, 152, 26-35. Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?©	4.1	31
133	Caroline Moreau <i>et al</i> . 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited Antioxidants and Redox	5.4	86
134	Signaling, 2018, 26, 742-748. Comment: Tau CSF proteins for diagnosis but tau PET imaging for AD diagnosis and staging. Neurology, 2018, 90, 216-216.	1.1	1
135	Online Preconcentration in Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal Fluid. Analytical Chemistry, 2018, 90, 2555-2563.	6.5	25
136	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Human Molecular Genetics, 2018, 27, 706-715.	2.9	30
137	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. Journal of Alzheimer's Disease, 2018, 63, 887-897.	2.6	16
138	Alpha-synuclein is present in dental calculus but not altered in Parkinson's disease patients in comparison to controls. Journal of Neurology, 2018, 265, 1334-1337.	3.6	1
139	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
140	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	6.2	40
141	Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathologica, 2018, 135, 681-694.	7.7	70
142	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
143	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
144	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89

#	Article	IF	CITATIONS
145	Clinical Reasoning: Rapidly progressive dementia in a patient with HIV after an exotic journey. Neurology, 2018, 91, e1360-e1364.	1.1	1
146	Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. Journal of Alzheimer's Disease, 2018, 66, 551-563.	2.6	46
147	Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications, 2018, 6, 108.	5.2	107
148	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
149	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of $\hat{Al^2}$ species. Neurolmage: Clinical, 2018, 20, 603-610.	2.7	11
150	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	2.5	68
151	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	10.1	1,177
152	Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. Annals of Neurology, 2018, 84, 347-360.	5.3	31
153	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	3.4	34
154	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
155	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). Frontiers in Aging Neuroscience, 2018, 10, 47.	3.4	13
156	Idiopathic Intracranial Hypertension Without Papilledema (IIHWOP) in Chronic Refractory Headache. Frontiers in Neurology, 2018, 9, 503.	2.4	28
157	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cellular and Molecular Life Sciences, 2018, 75, 4301-4319.	5.4	34
158	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimer's Research and Therapy, 2018, 10, 3.	6.2	76
159	Semen inhibits Zika virus infection of cells and tissues from the anogenital region. Nature Communications, 2018, 9, 2207.	12.8	41
160	Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. Journal of Proteome Research, 2018, 17, 516-523.	3.7	23
161	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	2.7	42
162	Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and AÎ ² 42 levels. Acta Neuropathologica, 2017, 133, 559-578.	7.7	129

#	Article	IF	CITATIONS
163	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.1	73
164	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	2.7	64
165	Polyâ€ <scp>GP</scp> in cerebrospinal fluid links <i>C9orf72</i> â€essociated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp> / <scp>FTD</scp> . EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
166	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics, 2017, 14, 499-514.	3.0	26
167	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
168	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108
169	Neurofilaments in blood. Neurology, 2017, 89, 2126-2127.	1.1	0
170	Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures. JACC: Cardiovascular Interventions, 2017, 10, 2297-2303.	2.9	136
171	Serum Interleukin-10 Levels Correlate with Cerebrospinal Fluid Amyloid Beta Deposition in Alzheimer Disease Patients. Neurodegenerative Diseases, 2017, 17, 227-234.	1.4	42
172	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics, 2017, 14, 769-777.	3.0	27
173	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. Alzheimer's Research and Therapy, 2017, 9, 17.	6.2	30
174	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
175	Superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus: a case report. Clinical Autonomic Research, 2017, 27, 63-66.	2.5	1
176	Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay. High-Throughput, 2017, 6, 18.	4.4	8
177	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	1.9	207
178	TDPâ€43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO Journal, 2016, 35, 2350-2370.	7.8	76
179	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	3.3	24
180	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	3.3	81

#	Article	IF	Citations
181	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. Journal of Neurology, 2016, 263, 954-960.	3.6	13
182	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
183	Amyloidâ€beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimer's and Dementia, 2016, 12, 996-1013.	0.8	17
184	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- \hat{l}^2 in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
185	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	2.4	21
186	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimerâ \in 2s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Molecular and Cellular Proteomics, 2016, 15, 3126-3138.	3.8	92
187	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German–Austrian retrospective multicenter study in patients with a clinically isolated syndrome. Journal of Neurology, 2016, 263, 2499-2504.	3.6	46
188	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	5.3	188
189	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. Movement Disorders, 2016, 31, 848-860.	3.9	52
190	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	3.9	26
191	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	3.7	207
192	Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 1353-1356.	3.1	2
193	Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. Journal of Alzheimer's Disease, 2016, 55, 1471-1480.	2.6	40
194	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL- $1\hat{l}^2$. BMC Neurology, 2016, 16, 185.	1.8	64
195	Aggregated α-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	3.8	17
196	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	2.8	26
197	<i>NEK1</i> mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	7.6	105
198	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. PLoS ONE, 2016, 11, e0164953.	2.5	21

#	Article	IF	Citations
199	An integrated microfluidic chip for immunocapture, preconcentration and separation of \hat{l}^2 -amyloid peptides. Biomicrofluidics, 2015, 9, 054117.	2.4	35
200	Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay. Scientific Reports, 2015, 5, 12767.	3.3	5
201	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. International Journal of Molecular Sciences, 2015, 16, 17565-17588.	4.1	20
202	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	2.3	21
203	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	3.1	64
204	The role of <i>TREM2</i> R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.8	152
205	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
206	Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. PLoS ONE, 2014, 9, e88680.	2.5	75
207	Intact Protein Analysis of Ubiquitin in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Differences in Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Proteome Research, 2014, 13, 4518-4525.	3.7	41
208	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	7.6	91
209	P1-163: DIFFERENTIAL SIALYLATION OF SERPIN A1, DETECTED BY NANOSCALE CAPILLARY ISOELECTRIC FOCUSING IN CEREBROSPINAL FLUID, AS AN EARLY DIAGNOSTIC MARKER OF PARKINSON'S DISEASE DEMENTIA., 2014, 10, P360-P360.		0
210	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
211	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische AnsÃæze in der Diagnose der Frontotemporalen LobÃædegeneration. Laboratoriums Medizin, 2012, 36, .	0.6	1
212	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.1	81
213	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. PLoS ONE, 2012, 7, e48783.	2.5	37
214	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt–Jakob disease. Proteomics, 2010, 10, 81-89.	2.2	39
215	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2009, 17, 541-551.	2.6	74
216	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods, 2008, 44, 289-298.	3.8	38

#	Article	IF	CITATION
217	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease. Neurobiology of Aging, 2006, 27, 10-15.	3.1	69
218	Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiology of Aging, 2004, 25, 273-281.	3.1	267
219	βâ€amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Annals of Neurology, 2003, 54, 263-267.	5. 3	82
220	Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software. Clinical Chemistry and Laboratory Medicine, 2001, 39, 324-32.	2.3	65